Efficacy of major ozone autohemotherapy in patients with post-COVID syndrome

Background and objectives It has been suggested that medical ozone treatment may be used for post-COVID syndrome, but there is still a lack of evidence. The aim of the study is to investigate the efficacy of medical ozone treatment in fatigue, anxiety, depression, quality of life, and quality of sleep in patients diagnosed with post-COVID syndrome. Materials and methods The study was designed as a retrospective medical records review study. It was conducted at Baskent University in patients who had been diagnosed with post-COVID syndrome and accepted 10 sessions of major ozone autohemotherapy. Demographic data, FACIT Fatigue Scale, Beck Depression Inventory, Beck Anxiety Inventory, Pittsburgh Sleep Quality Index, and Short Form−36 scores were obtained from the hospital database. The scores before and after treatment were compared statistically. p < 0.05 was revealed as statistically significant. Results A total of 40 patients were analyzed. Thirty two of them were female, and eight of them were male. It was determined that both Beck Anxiety Inventory and Beck Depression Inventory scores were decreased after ozone application ( p < 0.05). Statistically significant decreases in FACIT scores were obtained after 10 sessions of major blood ozonation ( p < 0.05). Additionally, improvement in all subscores of Short Form-36 was determined after the medical ozone treatment ( p < 0.05). Conclusion The patients suffering from post-COVID syndrome may benefit from major blood ozonation. The treatment may be one of the complementary treatments after COVID-19 infection.